|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0017262,
umls-concept:C0031082,
umls-concept:C0033684,
umls-concept:C0038952,
umls-concept:C0144576,
umls-concept:C0185117,
umls-concept:C0370003,
umls-concept:C0871261,
umls-concept:C1140680,
umls-concept:C1516213,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C2347026,
umls-concept:C2603343,
umls-concept:C2911684,
umls-concept:C2911692
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2004-3-29
|
|
pubmed:abstractText |
The role of MDR1 in clinical paclitaxel resistance remains poorly characterized. This study sought to identify the incidence and significance of P-glycoprotein (P-gp) over-expression on survival, tumor response to paclitaxel and the effect of prior cytotoxic exposure on P-gp expression in patients with paired primary and recurrent ovarian cancer samples.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0090-8258
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
93
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
98-106
|
|
pubmed:dateRevised |
2004-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:15047220-Adult,
pubmed-meshheading:15047220-Aged,
pubmed-meshheading:15047220-Antineoplastic Agents, Phytogenic,
pubmed-meshheading:15047220-Female,
pubmed-meshheading:15047220-Humans,
pubmed-meshheading:15047220-Immunohistochemistry,
pubmed-meshheading:15047220-Middle Aged,
pubmed-meshheading:15047220-Neoplasm Recurrence, Local,
pubmed-meshheading:15047220-Ovarian Neoplasms,
pubmed-meshheading:15047220-P-Glycoprotein,
pubmed-meshheading:15047220-Paclitaxel,
pubmed-meshheading:15047220-Retrospective Studies,
pubmed-meshheading:15047220-Survival Rate
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Expression of multidrug resistance-1 protein inversely correlates with paclitaxel response and survival in ovarian cancer patients: a study in serial samples.
|
|
pubmed:affiliation |
Division of Hematology/Oncology, Massachusetts General Hospital, Boston, MA 02114, USA.
|
|
pubmed:publicationType |
Journal Article
|
